Prolonged response to treatment with ipilimumab in a patient with a diagnosis of disseminated malignant melanoma

Abstract

Ipilimumab is a first immune checkpoints inhibitors. Ipilimumab is a standard therapy for advanced melanoma. In Poland the reimbursment of this drug includes only melanoma of the skin in the second line systemic therapy. We describe a case of a middle-age woman with a diagnosis of malignant disseminated melanoma (primary diagnosis was adenocarcinoma) in which the use of ipilimumab induction in second line treatment resulted long-term clinical benefit — 30 months free of the disease symptoms.